Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of low-dose AS03-adjuvanted H1N1 pandemic vaccine in children
2011-003512-23Phase 2
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Q-Pan H1N1 in influenza A virus infection (H1N1) (2 arms), sponsored by GSK. Primary endpoints: Humoral immune response against vaccine-homologous A/California (H1N1) and Immunologic equivalence between Quebec and Dresden vaccine formulations.
02
Drugs
Q-Pan H1N1
03
Conditions
influenza A virus infection (H1N1)
Beyond the preview
Go deeper on 2011-003512-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003512-23.